newsfilter
← Latest News
GlobeNewswire·

Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

Preclinical results demonstrate safe and efficient immune response with vaccine development showing promise of neutralizing activity for a range of variants LAWRENCEVILLE, N.J., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a